Author:
South Anna-Maria,Oller Devin,Lofwall Michelle,Fanucchi Laura C.
Abstract
Abstract
Persons with opioid use disorder (OUD) are receiving extended-release buprenorphine (ER-buprenorphine) for treatment of OUD. There are no clinical guidelines for management of patients with OUD on ER-buprenorphine experiencing acute or chronic pain. This case report describes 3 patient-involved, multidisciplinary approaches for pain management in various clinical scenarios, including a scheduled knee replacement, emergent surgery for an ischemic limb, and management of chronic pain from metastatic malignancy. These cases illustrate that adequate analgesia for patients who have received ER-buprenorphine is possible, and approaches can be individualized, with shared decision making between providers and patients addressing all barriers to optimize treatment outcomes. Options for acute pain management that can be considered include supplemental sublingual buprenorphine, nonopioid adjuncts, and short courses of full opioid agonists. Potential barriers that impact OUD and acute/chronic pain are provider bias, limited access to palliative care clinicians with addiction medicine training, and payor restrictions to adding sublingual buprenorphine for patients that are on ER-buprenorphine. Additional training for clinicians and other members of the health care team is recommended to improve patient-involved care of persons with OUD experiencing pain.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Pharmacology (medical),Psychiatry and Mental health
Reference13 articles.
1. Compassion inequities and opioid dependence: A matched case-control analysis of inpatient pain management for patients with a history of opioid use disorder hospitalized for cancer-related pain;J Pain Symptom Manage,2021
2. Management of opioid use disorder and associated conditions among hospitalized adults;J Hosp Med,2022
3. Continuation versus discontinuation of buprenorphine in the perioperative setting: A retrospective study;Cureus,2022
4. Weekly and monthly subcutaneous buprenorphine depot formulations vs daily sublingual buprenorphine with naloxone for treatment of opioid use disorder: A randomized clinical trial;JAMA Intern Med,2018
5. Treating opioid use disorder with a monthly subcutaneous buprenorphine depot injection: 12-Month safety, tolerability, and efficacy analysis;J Clin Psychopharmacol,2020